Global Information
회사소개 | 문의 | 비교리스트

흡입기 : 의료기기 파이프라인 평가

Inhalers - Medical Devices Pipeline Assessment, 2019

리서치사 GlobalData
발행일 2019년 05월 상품 코드 348464
페이지 정보 영문 357 Pages
가격
US $ 4,000 ₩ 4,753,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,000 ₩ 9,507,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 12,000 ₩ 14,260,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


흡입기 : 의료기기 파이프라인 평가 Inhalers - Medical Devices Pipeline Assessment, 2019
발행일 : 2019년 05월 페이지 정보 : 영문 357 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

흡입기(Inhalers) 파이프라인 제품에 대해 조사 분석했으며, 개발 단계별 비교 분석에 초점을 맞추어 파이프라인 제품 개발에 참여하고 있는 주요 기업, 진행중인 임상시험 관련 정보 등을 전해드립니다.

제1장 목차

제2장 서론

  • 흡입기 개요

제3장 개발중인 제품

  • 흡입기 - 파이프라인 제품 : 개발 단계별
  • 흡입기 - 파이프라인 제품 : 부문별
  • 흡입기 - 파이프라인 제품 : 지역별
  • 흡입기 - 파이프라인 제품 : 규제별
  • 흡입기 - 파이프라인 제품 : 승인 예정일별
  • 흡입기 - 진행중인 임상시험

제4장 흡입기 - 개발중인 파이프라인 제품 : 기업별

  • 흡입기 기업 - 파이프라인 제품 : 개발 단계별
  • 흡입기 - 파이프라인 제품 : 개발 단계별

제5장 흡입기 기업과 제품 개요

  • Adamis Pharmaceuticals Corporation
  • Advent Pharmaceuticals Pty Ltd
  • Aespira Ltd.
  • Akela Pharma Inc.(휴지중)
  • Alexza Pharmaceuticals, Inc.
  • Bayer HealthCare AG
  • Bellerophon Therapeutics LLC
  • Bespak Europe Ltd.
  • Cipla Ltd.
  • CN Creative
  • Drexel University
  • FocusStart Orthosensors
  • GlaxoSmithKline Plc
  • Hovione FarmaCiencia SA
  • MannKind Corporation
  • Medihale Ltd.
  • Nanotherapeutics, Inc.
  • Nektar Therapeutics
  • North Carolina State University
  • Novartis AG
  • OPKO Health, Inc.
  • Pharmaxis Limited
  • Respira Therapeutics, Inc.
  • Sandoz International GmbH
  • Sheffield Hallam University
  • Shin Nippon Biomedical Laboratories, Ltd.
  • SHL Medical
  • SkyePharma Plc
  • Teva Pharmaceutical Industries Limited
  • University of Kansas

제6장 흡입기 - 최근의 동향

제7장 부록

도표

KSM 16.01.25

List of Tables

  • Table 1: Inhalers - Pipeline Products by Stage of Development
  • Table 2: Inhalers - Pipeline Products by Segment
  • Table 3: Inhalers - Pipeline Products by Territory
  • Table 4: Inhalers - Pipeline Products by Regulatory Path
  • Table 5: Inhalers - Pipeline Products by Estimated Approval Date
  • Table 6: Inhalers - Ongoing Clinical Trials
  • Table 7: Inhalers Companies - Pipeline Products by Stage of Development
  • Table 8: Inhalers - Pipeline Products by Stage of Development
  • Table 9: Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 10: INBRIJA - Product Status
  • Table 11: INBRIJA - Product Description
  • Table 12: PLUMIAZ Nasal Spray Device - Product Status
  • Table 13: PLUMIAZ Nasal Spray Device - Product Description
  • Table 14: Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 15: Taper DPI - Product Status
  • Table 16: Taper DPI - Product Description
  • Table 17: Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 18: g60 Dry Powder Inhaler - Product Status
  • Table 19: g60 Dry Powder Inhaler - Product Description
  • Table 20: Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 21: resQhaler - Product Status
  • Table 22: resQhaler - Product Description
  • Table 23: AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 24: Fentanyl TAIFUN Inhaler - Product Status
  • Table 25: Fentanyl TAIFUN Inhaler - Product Description
  • Table 26: Alexza Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 27: Staccato System - Disposable Single Dose - Product Status
  • Table 28: Staccato System - Disposable Single Dose - Product Description
  • Table 29: Staccato System - Multiple Dose - Product Status
  • Table 30: Staccato System - Multiple Dose - Product Description
  • Table 31: Aradigm Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 32: Aerx Pure Nicotine Inhaler - Product Status
  • Table 33: Aerx Pure Nicotine Inhaler - Product Description
  • Table 34: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 35: Duaklir Genuair Metered Dose Inhaler - Product Status
  • Table 36: Duaklir Genuair Metered Dose Inhaler - Product Description
  • Table 37: Bayer AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 38: Ciprofloxacin Dry Powder Inhaler - Product Status
  • Table 39: Ciprofloxacin Dry Powder Inhaler - Product Description
  • Table 40: Bellerophon Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 41: Mark2 Device - Product Status
  • Table 42: Mark2 Device - Product Description
  • Table 43: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 44: VAL020 Metered Dose Inhaler Valve - Product Status
  • Table 45: VAL020 Metered Dose Inhaler Valve - Product Description
  • Table 46: Boehringer Ingelheim GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 47: Next Generation Respimat Inhaler - Product Status
  • Table 48: Next Generation Respimat Inhaler - Product Description
  • Table 49: Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 50: Tiotropium bromide DPI - Product Status
  • Table 51: Tiotropium bromide DPI - Product Description
  • Table 52: Drexel University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 53: BREATHE Inhaler - Product Status
  • Table 54: BREATHE Inhaler - Product Description
  • Table 55: Eli Lilly and Co Pipeline Products & Ongoing Clinical Trials Overview
  • Table 56: Nasal Glucagon Delivery System - Product Status
  • Table 57: Nasal Glucagon Delivery System - Product Description
  • Table 58: FocusStart LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 59: Smart Inhaler - Product Status
  • Table 60: Smart Inhaler - Product Description

List of Figures

  • Figure 1: Inhalers - Pipeline Products by Stage of Development
  • Figure 2: Inhalers - Pipeline Products by Segment
  • Figure 3: Inhalers - Pipeline Products by Territory
  • Figure 4: Inhalers - Pipeline Products by Regulatory Path
  • Figure 5: Inhalers - Pipeline Products by Estimated Approval Date
  • Figure 6: Inhalers - Ongoing Clinical Trials

GlobalData's Medical Devices sector report, "Inhalers - Medical Devices Pipeline Assessment, 2019" provides an overview of Inhalers currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inhalers pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Inhalers under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Inhalers and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Inhalers under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 Inhalers Overview

3 Products under Development

  • 3.1 Inhalers - Pipeline Products by Stage of Development
  • 3.2 Inhalers - Pipeline Products by Segment
  • 3.3 Inhalers - Pipeline Products by Territory
  • 3.4 Inhalers - Pipeline Products by Regulatory Path
  • 3.5 Inhalers - Pipeline Products by Estimated Approval Date
  • 3.6 Inhalers - Ongoing Clinical Trials

4 Inhalers - Pipeline Products under Development by Companies

  • 4.1 Inhalers Companies - Pipeline Products by Stage of Development
  • 4.2 Inhalers - Pipeline Products by Stage of Development

5 Inhalers Companies and Product Overview

  • 5.1 Acorda Therapeutics Inc Company Overview
  • 5.2 Adamis Pharmaceuticals Corp Company Overview
  • 5.3 Advent Pharmaceuticals Pty Ltd Company Overview
  • 5.4 Aespira Ltd. Company Overview
  • 5.5 AKELA Pharma Inc. (Inactive) Company Overview
  • 5.6 Alexza Pharmaceuticals Inc Company Overview
  • 5.7 Aradigm Corp Company Overview
  • 5.8 AstraZeneca Plc Company Overview
  • 5.9 Bayer AG Company Overview
  • 5.10 Bellerophon Therapeutics Inc Company Overview
  • 5.11 Bespak Europe Ltd Company Overview
  • 5.12 Boehringer Ingelheim GmbH Company Overview
  • 5.13 Circassia Pharmaceuticals Plc Company Overview
  • 5.14 Drexel University Company Overview
  • 5.15 Eli Lilly and Co Company Overview
  • 5.16 FocusStart LLC Company Overview
  • 5.17 GlaxoSmithKline Plc Company Overview
  • 5.18 Lupin Pharmaceuticals Inc Company Overview
  • 5.19 MannKind Corp Company Overview
  • 5.20 Medihale Ltd (Inactive) Company Overview
  • 5.21 Monash University Company Overview
  • 5.22 Nektar Therapeutics Company Overview
  • 5.23 North Carolina State University Company Overview
  • 5.24 Novartis AG Company Overview
  • 5.25 Ology Bioservices Inc Company Overview
  • 5.26 OPKO Health Inc Company Overview
  • 5.27 OtiTopic LLC Company Overview
  • 5.28 Perrigo Co Plc Company Overview
  • 5.29 Pharmaxis Ltd Company Overview
  • 5.30 Pneuma Respiratory Inc Company Overview
  • 5.31 Resolve Digital Health Inc Company Overview
  • 5.32 Respira Therapeutics Inc Company Overview
  • 5.33 Sandoz International GmbH Company Overview
  • 5.34 Seng Vital International GmbH Company Overview
  • 5.35 Senzer Ltd Company Overview
  • 5.36 Sheffield Hallam University Company Overview
  • 5.37 Softhale NV Company Overview
  • 5.38 Spyryx Biosciences Inc Company Overview
  • 5.39 Sun Pharma Advanced Research Company Ltd Company Overview
  • 5.40 Syqe Medical Company Overview
  • 5.41 Tetra Bio-Pharma Inc Company Overview
  • 5.42 Teva Pharmaceutical Industries Ltd Company Overview
  • 5.43 United Therapeutics Corp Company Overview
  • 5.44 University of Kansas Company Overview
  • 5.45 University of Sydney Company Overview
  • 5.46 University of Texas Medical Branch at Galveston Company Overview
  • 5.47 Uscom Ltd. Company Overview
  • 5.48 Vectura Group Plc Company Overview
  • 5.49 Verona Pharma Plc Company Overview
  • 5.50 Virginia Commonwealth University Company Overview

6 Inhalers- Recent Developments

  • 6.1 May 04, 2019: Vectura wins US GSK patent litigation and awarded $89.7Million in damages by trial jury
  • 6.2 May 04, 2019: Vectura wins US GSK Patent Litigation and awarded $89.7Million in damages by Trial Jury
  • 6.3 May 03, 2019: Novo Nordisk's operating profit increased by 14% in Danish kroner and by 8% at constant exchange rates (CER) in the first three months of 2019
  • 6.4 May 02, 2019: Teva reports first quarter 2019 financial results
  • 6.5 May 01, 2019: United Therapeutics reports first quarter 2019 financial results
  • 6.6 May 01, 2019: GSK delivers sales of £7.7 billion +6% AER, +5% CER
  • 6.7 Apr 30, 2019: Novo Nordisk to achieve target of 100% renewable power in production and launches new ambition aiming for zero environmental impact
  • 6.8 Apr 30, 2019: Adherium: Appendix 4C- Quarterly cash flow report to 31 March 2019
  • 6.9 Apr 25, 2019: 3M reports first-quarter 2019 results; company initiates restructuring
  • 6.10 Apr 25, 2019: Orion Group Interim report January-March 2019

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer
Back to Top
전화 문의
F A Q